Extraordinary General Meeting to address the proposal by a group of shareholders that Diamyd Medical enter into immediate liquidation

On February 8, 2013, a group of shareholders submitted a request in writing to
the Board of Directors of Diamyd Medical that the Board convene an extraordinary
General Meeting to address their proposal that Diamyd Medical enter into
immediate liquidation. The shareholders claimed to represent 8,883,351 Series B
shares in Diamyd, corresponding to about 21 percent of the votes and 30 percent
of the total number of shares.

In addition to the proposed liquidation, the group of shareholders proposes that
the General Meeting elect a new Board of Directors, that the company change its
name to Diamyd Sverige AB (publ) and that the General Meeting submit
instructions to the Board to establish a wholly owned subsidiary, which is to
have the same number of shares as Diamyd and only one class of share. Diamyd
should transfer all of its share holdings and about SEK 40,000,000 in cash to
this subsidiary.

Due to this request, the Board of Directors has decided to convene an
Extraordinary General Meeting on Wednesday, March 13, 2013. Summons will be
published in Post- och Inrikes Tidningar on February 13, 2013. The summons and
the letter from the shareholders is available at Diamyd’s website,
www.diamyd.com.
For more information, please contact:
Anders Essen-Möller, Chairman Diamyd Medical AB
Phone: 070-551 0679, E-mail:anders.essen-moller@diamyd.com
About Diamyd Medical
Diamyd Medical was founded in 1996 and is active in the field of pharmaceutical
development. Diamyd Medical is headquartered in Stockholm, Sweden. The Company’s
development project consists of the protein GAD for the treatment and prevention
of autoimmune diabetes. A Swedish researcher-initiated Phase II study is ongoing
to evaluate whether GAD can prevent type 1 diabetes in children who are at high
risk of developing the disease.

Diamyd Medical also has holdings in the gene therapy company Periphagen
Holdings, Inc. (USA), the vaccine company Protein Sciences Corporation (USA) and
the diagnostics company Mercodia AB (Sweden).

Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker:
DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC
Markets and the Bank of New York Mellon (PAL). Further information is available
on the Company’s website: www.diamyd.com.

This information is disclosed in accordance with the Swedish Securities Markets
Act, the Swedish Financial Instruments Trading Act, or the requirements stated
in the listing agreements.

Diamyd Medical AB (publ)
Karlavägen 108, SE-115 26 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. Reg. no: 556530-1420